ACC makes updates to executive staff

The American College of Cardiology on Jan. 13 announced a handful of changes to its executive staff, including promotions and structural changes within the ACC’s senior team.

According to a release from the College, John Rumsfeld, MD, PhD, the ACC’s chief innovation officer, was recently named the organization’s chief science and quality officer. The new position will reportedly require Rumsfeld to be the “physician architect and leader” of the ACC’s science- and quality-focused efforts in addition to his clinical and academic positions at the Denver VA Medical Center and University of Colorado School of Medicine.

Brendan Mullen, who previously served as the ACC’s executive vice president and the senior director for the PINNACLE Registry, has been promoted to senior executive vice president, where he’ll oversee “several divisions” within the College. He’ll be joined by new executive vice president Janice Sibley, who will oversee the ACC’s education and publishing divisions, including the JACC family of journals. Prior to working with the ACC Mullen was a consultant for the Advisory Board Company and vice president of programs and strategy at the National Quality Forum; Sibley worked in scientific and continuing medical education for more than 30 years.

Julia Chang, MS, MBA, was the fourth staffer to snag a promotion—to executive vice president of the ACC’s science and quality division. In the role, Chang will be responsible for operational oversight of clinical registries, hospital accreditation, clinical policy, quality improvement and patient education. Prior to her time at the ACC, which also included a stint as division vice president for science and quality, she was a senior manager in IBM’s strategy consulting unit.

""

After graduating from Indiana University-Bloomington with a bachelor’s in journalism, Anicka joined TriMed’s Chicago team in 2017 covering cardiology. Close to her heart is long-form journalism, Pilot G-2 pens, dark chocolate and her dog Harper Lee.

Around the web

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.

If President Trump initiates a 25% tariff against pharmaceuticals imported from Ireland, it might impact the price for X-ray iodine contrast agents in the U.S. depending what rules are put in place.

The imaging manufacturer expects to spend between $227 million and $340 million on tariff mitigation efforts, leaders said Wednesday.